Roivant Sciences (NASDAQ: ROIV)
Roivant Sciences Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Roivant Sciences Company Info
Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. Its product portfolio includes Vtama, Batoclimab, Brepocitinib, Namilumab, and RVT-2001, which aims to treat psoriasis, atopic dermatitis, thyroid eye disease, and other illnesses. The company was founded by Vivek Ramaswamy on April 7, 2014 and is headquartered in London, the United Kingdom.
News & Analysis
Roivant Sciences Posts Mixed Q2
Roivant Sciences reports improved EPS for the second quarter, showing drug development progress and rising expenses.
It's Hard to Be a Biotech Bull in This Market, but This Stock Is a Buy
The market's dour reaction to Roivant Sciences' latest deal doesn't add up.
2 Magnificient Growth Stocks I'm Buying in August
These biotech stocks could markedly outperform the broader market.
Why Shares of Roivant Sciences Rose Wednesday
The pharmaceutical company released fourth-quarter earnings.
Why Roivant Sciences Stock Is Perking Up Today
Positive long-term data for a novel ulcerative colitis medication is fueling a double-digit rise in the drugmaker's stock.
Why Shares of Roivant Sciences Jumped This Week
The company's stock benefited from another company's buyout.
Why Shares of Roivant Sciences Were Down Tuesday
After a run-up last week prompted by positive clinical trial results, the stock has given back its recent gains.
Why Roivant Sciences' Shares Are Up Thursday
The company is collaborating with Pfizer to create a portfolio company to develop an encouraging drug to treat ulcerative colitis.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.